| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -713.4% | -155.3% |
| ROCE | n/a |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 0.5 | 0.2 |
| Pr/Book | 0.3 |
| Latest | F'cast | |
|---|---|---|
| Revenue | -74.5% | 120.0% |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-08 | 0.93 | (17.60) | (8.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-09 | 1.39 | (20.21) | (9.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-10 | 0.76 | (16.94) | (6.77)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-11 | 7.13 | (4.44) | (1.80)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-12 | 1.82 | (12.96) | (6.20)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-13 | 4.00 | (6.21) | (2.60)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-14 | 4.80 | (6.38) | (2.80)p | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2013 FactSet Research Systems Inc. All rights reserved.
| Second Price Monitoring Extn | 14-Jun-2013 | 16:40 | RNS |
| Price Monitoring Extension | 14-Jun-2013 | 16:35 | RNS |
| Blocklisting Six Monthly Return | 04-Jun-2013 | 14:48 | RNS |
| Ark gains on hopes for cancer drug | 31-Jul-2008 | The Independent |
| Need to know | 31-May-2008 | Times |
| Ark perks up after regulators say brain tumour g... | 06-Jan-2007 | Telegraph |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 0.43p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 3.58 |
| 52 Week Low | 0.36 |
| Volume | 0 |
| Shares Issued | 209.28m |
| Market Cap | £0.90m |
| Beta | 0.31 |
| RiskGrade | 677 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| CEO | Martyn Williams |
| CFO | Russell Banks |
You are here: research